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Abstract
The majority of diseases causing sudden death or sudden onset of serious 
restriction of quality of life are thrombotic disease. Myocardial infarction is often 
caused by thrombotic occlusion of coronary arterial branches. Ischemic stroke is 
also caused by occlusion of cerebral arteries with thrombi. In patients admitted to 
the hospital and immobility, venous thromboembolism causing pulmonary embo-
lism is a major cause of death. The risk of cardiovascular events is influenced by 
food intake. Yet, the mechanism between specific food intake and the risk of throm-
botic disease is still to be elucidated. Recent progress of computer and information 
technology allows us to describe complex biological phenomena such as thrombosis 
from basic principles of physics and chemistry. Coupling blood flow, platelet, 
coagulation, and fibrinolysis allows us to understand the contributing role of each 
factor for thrombus formation. Yet, the precise role of food intake to influence the 
risk of thrombosis is still to be elucidated. Coupling basic research and large-scale 
clinical research will further clarify the role of various types of food intake in the 
risk of thrombosis.
Keywords: myocardial infarction, stroke, arterial thrombosis, platelet, coagulation
1. Introduction
Thrombosis is the leading cause of death in the world. Indeed, atherothrombosis 
including coronary artery diseases and cerebrovascular diseases is the top cause of 
death in various regions of the world [1]. Venous thrombosis including deep venous 
thrombosis and pulmonary embolism is the third cause of death in hospitalized 
patients [2]. Thrombosis is a disease caused by thrombi formed at various ves-
sels. The major symptom differs substantially depending upon the site where the 
thrombi developed. Typically, arterial thrombosis such as myocardial infarction 
and ischemic stroke is symptomatic even when the thrombi are small (e.g., less than 
1 mm in diameter) [3]. On the other hand, venous thrombosis is asymptomatic until 
thrombi become substantially large such as the ones that occlude several pulmonary 
arteries to cause pulmonary embolism [4]. In both arterial and venous thromboses, 
platelets are cells that contribute to initial thrombus formation. Coagulation and 
fibrinolysis are systems necessary to regulate the size of fibrin thrombi.
It is noteworthy that there is homogeneity in risk factors for various arte-
rial/venous thromboses despite wide variation of clinical manifestation [5]. 
Framingham study demonstrated that cigarette smoking, diabetes mellitus (DM), 
dyslipidemia, and hypertension are strong predictors for the future onset of arterial 
thrombosis represented by acute myocardial infarction [6]. Recent international 
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registries also confirm that these risk factors are contributing factors for the recur-
rence of cardiovascular events [7]. Moreover, international registries also suggested 
these parameters as risk factors of venous thrombosis [8]. These clinical observa-
tions suggested the presence of common pathways for the onset of arterial and 
venous thrombosis [9].
The Framingham registry suggested the contributory role of obesity and less 
exercise as the predictors for future prevalence of risk factors. These abnormali-
ties represented as visceral obesity-related syndrome is named as “metabolic 
syndrome.” In metabolic syndrome patients, insulin resistance is one of the major 
contributors [10]. Increased body weight, high blood pressure, and dyslipidemia 
are common manifestations of metabolic syndrome. Long-term exposure to a high-
calorie diet and lack of good exercise are supposed as underlining mechanisms 
for the onset of metabolic syndromes. The risk of thrombotic disease including 
arterial and venous thrombosis is speculated to be high in patients with metabolic 
syndrome.
2. Platelet adhesion at the site of endothelial injuries
Blood is flowing to maintain homeostasis inside the human body. Blood cells 
have specific functions: erythrocytes bring oxygen to tissues, leukocytes protect 
from infection, and platelets stop bleeding promptly. As shown in Figure 1, large 
and heavy erythrocytes tend to be located in the center of blood flow. Small cells 
of platelets circulate interacting with endothelial cells [11]. In the case where 
endothelial cells have a physiological function, platelets do not interact with 
them [12]. Platelets collide with the vessel wall and promptly go back to the 
blood flow without platelet activation. On the other hand, when endothelial cell 
function was disturbed by physical or chemical stimuli, endothelial cells lose 
their ability to keep antithrombotic function. Then, platelets immediately start 
the interaction with endothelial cells [12]. At the time, von Willebrand factor 
(VWF) is expressed on the cell surface of stimulated endothelial cells. Platelets 
capture VWF through glycoprotein (GP)Ibα. GPIbα is expressed on the surface 
Figure 1. 
Role of erythrocytes and blood flow in platelet adhesion at the site of endothelial injury. This figure 
demonstrates the three-dimensional distribution of erythrocytes, platelets, and endothelial cells. Erythrocytes 
accumulate in the center of blood flow by biorheological effects. Accordingly, platelets circulate close to 
endothelial cells. In the presence of normally functioning endothelial cells, platelets do not adhere nor are 
activated, but just return to blood flow (panel A). If the endothelial cell function was disturbed by various 
stimulations, platelets are adhered and activated through their interaction with von Willebrand factor (VWF).
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of platelet regardless if they are activated or not [13]. Thus, initial adhesion of 
platelets at the site of endothelial cell damage occurs predominantly as a physical 
phenomenon, which occurs immediately without time-consuming biological 
process. Historically, the vast majority of vessel damage is caused by trauma. 
Rapid accumulation of platelets at the site of endothelial injury plays an impor-
tant role to keep our blood in our vessel system for surviving.
The potential impact of erythrocytes for the onset and growth of thrombosis 
has first caught the interest of researchers in the 1960s [14]. Biorheological axial 
accumulation of flowing platelets was also recognized at the same time [15]. 
Clinical studies also support the notion that higher hematocrit values are related to 
higher risk of thrombotic diseases such as myocardial infarction [16]. These results 
strongly suggest the biophysical role of erythrocytes for thrombus formation. These 
rheological effects could hardly be controlled by food intake. In another aspect, 
erythrocytes also influence the function of platelet with biochemical modulation 
[17–19]. Indeed, erythrocytes are a huge source of ADP [20], which is one of the 
most potent platelet-stimulating agents [21, 22]. There is potential effects of food 
intake for influencing erythrocytes components which can influence thrombogenic-
ity of platelet [23, 24].
Recent advances in computer technology allowed us to predict the structure 
and function of VWF bound with GPIbα from the physical movement of atoms 
and water molecules [25, 26]. By the method, physical force generated by VWF 
binding with GPIbα could be predicted. Platelet adhesion at injured vessel wall is 
summarized in Figure 2. Platelets are cells with a diameter of approximately 5 μm. 
But, when platelet adhered at the site of vessel damage, only part of platelet bound 
with VWF. Molecular dynamic prediction revealed that single bond of VWF and 
GPIbα could generate binding force approximately 70 pN [25]. Fluid dynamic force 
applied to platelets reaches to a couple hundred pN when the cell receives detach-
ing force from arterial blood flow. Theoretically, several bonds between VWF and 
GPIbα are enough to stop platelets from adhering to the vessel wall. The mechanism 
of thrombus formation is a complicated process, but platelet adhesion under blood 
flow condition could now be constructed from physical movement of atoms and 
water molecules.
Figure 2. 
Platelet adhesion at the site of endothelial damage under blood flow conditions. Platelet adhesion is mediated 
exclusively by its glycoprotein (GP)Ibα binding with von Willebrand factor (VWF). Adhered platelets receive 
fluid dynamic force, but platelets continue to adhere until the detaching force becomes larger than the binding 
force generated between VWF and GPIbα.
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It is of particular importance that endothelial damage is not caused only by acute 
physical or chemical stimulation. In the recent era, human beings enjoy longer life 
than those who lived hundreds of years ago. Just like carrying human being, vessel 
system become old when people become old. Longer time exposure of vessel wall 
to atherogenic lipids such as LDL cholesterol and its related local biological reac-
tion causes atherosclerosis [27, 28]. Antithrombotic potential of endothelial cell in 
patients with atherosclerosis is reduced when compared to younger normal ones. 
Moreover, plaque rupture exposes subendothelial thrombotic materials to vessel 
lumen. Thus, atherothrombotic events occur frequently [29] in the era of aging 
society. The initial event resulting in symptomatic atherothrombosis is always 
platelet adhesion at the site of endothelial injury.
By understanding the mechanism of atherosclerosis and atherothrombosis, it 
is rather easy to understand that various types of food intake influence the risk 
of thrombosis. As regards nutritional factor, there is a hot discussion concerning 
cholesterol. Some suggested potential benefit of cholesterol restriction for preven-
tion of atherothrombosis. The other suggest there are no relationship between daily 
cholesterol  intake and the risk of atherothrombotic event risk.
3. Activation of coagulation cascade and fibrinolysis
Symptomatic atherothrombotic events such as acute myocardial infarction occur 
when organ perfusing arterial branch was occluded by thrombi. The diameter of 
organ perfusing vessels is substantially larger than a single cell of platelet. Indeed, 
the diameter of platelets is just 2–5 μm, while the diameter of myocardial perfusing 
coronary arterial branches is 2–3 mm. The size of vessel diameter is typically 1000 
more than the size of platelet diameter. It is nonrealistic to imagine that coronary 
arterial branches were occluded by platelet thrombi. Indeed, when coronary arte-
rial thrombi causing myocardial infarction are aspirated by thrombo-aspiration 
therapy, the main component of occlusive thrombi was fibrin (Figure 3). It is 
Figure 3. 
Major components of thrombi causing acute myocardial infarction. Sample thrombi were aspirated from 
patients with acute myocardial infarction. The main results and study protocols were published elsewhere [53]. 
Here, electron microscopy results are shown. Fibrin fibrils could be seen around activated platelets (arrow).
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noteworthy that fibrin fibrils are detected around activated platelets (Figure 3 is the 
product in collaboration with Prof. Yujiro Asada at Miyazaki University).
The lipid components of activated platelet changed from the ones at the quiescent 
state. Negatively charged phospholipids appeared on the surface of activated platelets 
[22]. Then, various coagulation factors accumulated around the lipid to form pro-
thrombin complex. On the activated platelet, thrombin generation occurs extremely 
efficiently. Indeed, thrombin generation rate in the absence of activated platelet and 
tissue factor is almost 0 as compared to that in its presence. At the site of atheroma 
rupture, large enough fibrin thrombi were formed as a result of the accumulation of 
activated platelet and exposure of tissue factor from the ruptured atheroma. Tissue 
factor accumulated in the atheroma is generated from inflammatory cells, which 
migrated into the atheroma. In the animal study, dietary lipid restriction reduces the 
amount of tissue factor accumulated in the atheroma [30]. The clinical factor of the 
reduction of the onset of myocardial infarction by the use of lipid-lowering therapy 
[31] may be related to reduction of lipid accumulation and subsequent reduction in 
tissue factor accumulated in the atheroma. Moreover, there are several publications 
indicating the impact of food intake for the lipid component of blood cells [23, 24]. 
The rate of fibrin formation at the site of endothelial damage and platelet accumula-
tion should be modified by food from both activated platelet-derived procoagulant 
activity and the amount of tissue factors accumulated in the atheroma.
The process of thrombus formation at the site of endothelial injury is com-
plex. We have attempted to develop the process model of thrombus formation as 
shown in Figure 4 [32]. The model is still simple but includes various physically 
and chemically different events. First, the model implemented the effect of blood 
flow, which is a purely physical phenomenon. Second, the model includes platelet 
Figure 4. 
Coupling model of blood flow, platelet, coagulation, and fibrinolysis. Thrombus formation at the site of 
endothelial injury is modeled. Nonactivated platelets (NP) adhered at the site of endothelial injury through 
von Willebrand factor (VWF) and collagen are exposed there. NP become activated platelets (AP) by 
their interaction with VWF/collagen (①). AP has a potential to convert prothrombin to thrombin on their 
membrane surface (②). After production of thrombin from prothrombin (③), thrombin converts soluble 
fibrinogen to fibrin thrombi. (④) thrombin also has a function to further activate platelets through thrombin 
receptor stimulation. (⑤) Fibrinolytic system is also incorporated in this model. Functional endothelial cells 
constitutively release both tissue-type plasminogen activator (t-PA: ⑥) and plasminogen activator inhibitor 
(PAI)-1 (⑦). T-PA converts plasminogen to plasmin, which has fibrinolytic activity (⑧) unless inactivated by 
binding with PAI-1. Plasmin is a strong enzyme able to degrade fibrin. Its function is immediately neutralized 
by its binding with a2-plasmin inhibitor to form plasmin a2-plasmin inhibitor complex (PIC: ⑨).
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adhesion and activation. Platelet adhesion is implemented to be medicated by its 
GPIbα binding with von Willebrand factor (VWF) (① in Figure 4). GPIbα bind-
ing with VWF is a chemical phenomenon, but the binding force is a physical one. 
We have implemented both in the same model. Platelets were implemented to be 
activated to change their biological roles (② in Figure 4). This process is a biological 
process. The detailed process model of platelet activation was published elsewhere 
[33]. Briefly, platelets were settled to be captured by VWF under blood flow condi-
tion. Collagen exposed at the site of endothelial injury also interacts with platelet 
and contributed to platelet activation through its receptor, namely, GPVI [34]. 
Then, activated platelet was settled to have stronger capacity to bind with injured 
vessel wall, cohesion each other, and possess the capacity to express coagulogenic 
phospholipids. Then, prothrombin conversion to thrombin was settled to occur only 
on the surface of activated platelets (③ in Figure 4). Thrombin function is neutral-
ized promptly by its interaction with antithrombin III. Thrombin implemented to 
have function to convert fibrinogen to fibrin (④ in Figure 4) and further activated 
platelet through thrombin receptor stimulations [35].
There are several coagulation factors, the function of which is regulated strongly 
by food intake. Gla-domain of coagulation factors plays crucial roles in the accumu-
lation of coagulation factors around exposed negatively charged phospholipids on 
activated platelets [36]. Gla-domain also plays crucial roles for enzymatic func-
tion of coagulation factors. Carboxylation of Gla-domain is mediated by vitamin 
K. Thus, coagulation cascade does not work well in the absence of vitamin K or 
in patients taking vitamin K inhibitor. It is noteworthy that there are many foods 
including fermented food that are known to contain abundant vitamin K. Strict 
food restriction is necessary to keep the anticoagulant effects of vitamin K inhibi-
tors. Recently, a larger load of vitamin K on health is cautioned [37].
The amount of fibrin formed at the site of endothelial injury was reduced by the 
effect of intrinsic fibrinolysis. Fibrinolysis is a complex pathway, but the details of 
which is simplified to be incorporated as shown in Figure 4. Vascular endothelial cells 
have balanced roles for fibrinolysis by releasing both fibrinolytic tissue-type plas-
minogen activator (t-PA: ⑥) and the one has antifibrinolytic effects of plasminogen 
activator inhibitor (PAI)-1 (⑦). Both of them are constitutively released from endo-
thelial cells. But the rates of their releases were individually controlled in individual 
endothelial cells. When the rate of t-PA release increases, the amount of fibrin formed 
around the endothelial cells becomes smaller. It becomes larger in the case when 
the rate of PAI-1 release increases. Free t-PA has a potential to convert plasminogen 
to plasmin. (⑧) Plasmin is a strong protease, which can dissolve many functional 
proteins including fibrinogen. To avoid too much protein degradation, activity of 
plasmin is promptly neutralized by the function of α2-plasmin inhibitor (α2-PI: ⑨).
Previous publication suggested increased PAI-1 release after acute myocardial 
infarction and its role for the increased recurrence of myocardial infarction [38]. 
Animal experiments revealed that the food coloring agent of crocin reduces activ-
ity of PAI-1 and prevents thrombosis [39]. In human, increased PAI-1 activity is 
reported at the time of too much intake of fat [40]. Total fibrinolytic activity in 
humans is also reported to be low in obese patients [41]. Decreased fibrinolytic 
activity in patients taking too much lipid is one potential reason of increased risk of 
thrombosis in these patients.
4. Role of various types of food intake for the risk of thrombosis
There are many reports suggesting the increase/decrease in the risk of throm-
bosis by various food and beverage intake. Framingham study suggested that coffee 
7Mechanism of Thrombus Formation in Regard to Diet
DOI: http://dx.doi.org/10.5772/intechopen.92382
consumption is related to lower risk of myocardial infarction [42]. However, the 
influence of coffee intake for the onset and recurrence of myocardial infarction is 
still under discussion because other reports suggested higher rate of sudden cardiac 
death in coffee intake in patients after myocardial infarction [43]. People have con-
sensus that food intake should influence the risk of arterial and venous thrombosis. 
The problem is that it is still hard to state which food reduces/increases the risk of 
thrombosis.
Old epidemiological studies suggested that the risk of myocardial infarction 
increased in Japanese people who immigrated to Hawaii or California than that of 
the ones staying in Japan. They have the same genetic background. Environmental 
factors including food should contribute to the change in the risk of population 
when moved to the US than staying in Japan. Lower cardiovascular death rate in 
Japan is still noted in the international registry of patients with atherothrombosis 
or non-valvular atrial fibrillation. Despite epidemiological data, it is still hard to 
identify what food specifically modulated the rate of thrombosis.
There are many specific diets that potentially influence thrombotic risk. Among 
them, sodium intake should be one of the most established factors to avoid car-
diovascular diseases. Low sodium intake clearly decreases the risk of heart failure 
[44], but its direct effects for thrombosis is still to be elucidated. Mediterranean 
diet is also related to lower risk of cardiovascular diseases [45]. But it is still difficult 
to identify the specific content of Mediterranean diet related to the reduction in 
the risk of CV disease. A plant-based diet seems beneficial in reducing the risk of 
cardiovascular disease, but it has both good qualities and bad qualities [46]. The 
relationship between food and the risk of cardiovascular diseases (mostly arterial 
thrombosis) is complex.
A recent publication suggested the positive correlation between red and pro-
cessed meat intake and risk of cardiovascular diseases. This study also suggested the 
negative relationship between the intake of yogurt, cheese, and eggs and CV disease 
risk [47]. The observation study is useful to find potential contributing factors but 
still includes many potential biases. Just like drug or medical intervention, random-
ized trials comparing a variety of food intake with hard endpoint of cardiovascular 
death, myocardial infarction, and ischemic stroke will give us more insight. 
However, in reality, it is hard to design such trials because people have the right 
to eat whatever they like. It is hard to make a restriction in food intake for a long 
period of time. The combination of observational study and the study to clarify the 
mechanism will give us the best available evidence now.
5. Metabolic syndrome and thrombosis: view from the mechanism
Metabolic syndrome is characterized as the presence of three apparent character-
istics including visceral obesity manifested as increasing waist circumference, dyslip-
idemia, hypertension, and high blood glucose. Underlining pathophysiology is insulin 
resistance and lipid accumulation. It is noteworthy that various cytokines (adipocyto-
kines) were identified from adipose tissue. Adiponectin is the one identified as factor 
reducing the risk of thrombosis by preventing endothelial dysfunction [48]. Indeed, 
decreased plasma concentration of adiponectin observed in obese patients may suggest 
the potential regulatory role of adiponectin for the onset of thrombotic diseases [49]. 
Despite difficulty in understanding the precise relationship among various cytokines 
and adiponectin [50], an apparent link between metabolic syndrome and decreased 
adiponectin is noteworthy. Various parameters for coagulation and fibrinolysis are also 
influenced in metabolic syndrome patients [51]. It is reasonable to recommend regular 
exercise to prevent metabolic syndrome and future onset of thrombosis [52].
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6. Conclusion
Obviously, food intake influences deeply the risk of thrombotic disease such as 
arterial and venous thrombotic diseases. Deeply reliable population-based clinical 
trials or nicely designed registry studies are awaited. Precise understand the mecha-
nism of thrombotic disease from hard science such as re-construction of biological 
phenomena from the physical movement of atoms.
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